StageSeries C | Alive
Last Raised$20M | 15 yrs ago
About Arbor Surgical Technologies
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Missing: Arbor Surgical Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Arbor Surgical Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Arbor Surgical Technologies Patents
Arbor Surgical Technologies has filed 4 patents.
Prosthetics, Implants (medicine), Cardiac surgery, Chelating agents, Cell biology
Prosthetics, Implants (medicine), Cardiac surgery, Chelating agents, Cell biology
Arbor Surgical Technologies Frequently Asked Questions (FAQ)
When was Arbor Surgical Technologies founded?
Arbor Surgical Technologies was founded in 2002.
Where is Arbor Surgical Technologies's headquarters?
Arbor Surgical Technologies's headquarters is located at 22 Morgan Avenue, Irvine.
What is Arbor Surgical Technologies's latest funding round?
Arbor Surgical Technologies's latest funding round is Series C.
How much did Arbor Surgical Technologies raise?
Arbor Surgical Technologies raised a total of $54M.
Who are the investors of Arbor Surgical Technologies?
Investors of Arbor Surgical Technologies include Kaiser Permanente Ventures, Delphi Ventures, Alloy Ventures, Johnson & Johnson Innovation, Fisk Ventures and 8 more.
Who are Arbor Surgical Technologies's competitors?
Competitors of Arbor Surgical Technologies include AngelMed, EndoGastric Solutions, NeoChord, OrthAlign, CSA Medical, Mitralign, Dextera Surgical, Spectranetics, Symetis, Coherex Medical and 42 more.
Compare Arbor Surgical Technologies to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Surgi-Vision, Inc. is engaged in the development of sighting and visualization systems that allow a magnified stereoscopic vision of the surgical field and visualization of other intra-operative digital data during minimally invasive procedures. Surgi-Vision manufacturers specialized MRI coils that are used to take images from inside the body. Surgi-Vision received 510K clearance from the Food & Drug Administration (FDA) for clinical use of a new coil to image the esophagus and aorta.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.